Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Pharmacology of iron transport.

Byrne SL, Krishnamurthy D, Wessling-Resnick M.

Annu Rev Pharmacol Toxicol. 2013;53:17-36. doi: 10.1146/annurev-pharmtox-010611-134648. Epub 2012 Sep 27. Review.

PMID:
23020294
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

O'Donnell PH, Stadler WM.

Clin Cancer Res. 2012 May 15;18(10):2809-16. doi: 10.1158/1078-0432.CCR-11-2445. Epub 2012 Mar 16. Review.

PMID:
22427349
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Impact of terminal dimethylation on the resistance profile of ╬▒-N-heterocyclic thiosemicarbazones.

Heffeter P, Pirker C, Kowol CR, Herrman G, Dornetshuber R, Miklos W, Jungwirth U, Koellensperger G, Keppler BK, Berger W.

Biochem Pharmacol. 2012 Jun 15;83(12):1623-33. doi: 10.1016/j.bcp.2012.03.004. Epub 2012 Mar 15.

PMID:
22426010
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

PMID:
22105720
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Yu Y, Suryo Rahmanto Y, Richardson DR.

Br J Pharmacol. 2012 Jan;165(1):148-66. doi: 10.1111/j.1476-5381.2011.01526.x.

PMID:
21658021
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.

Kolesar JM, Sachidanandam K, Schelman WR, Eickhoff J, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE.

Exp Ther Med. 2011 Jan;2(1):119-123.

PMID:
21373381
[PubMed]
Free PMC Article
7.

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME.

Cancer Chemother Pharmacol. 2011 Aug;68(2):379-88. doi: 10.1007/s00280-010-1481-z. Epub 2010 Oct 28.

PMID:
20981545
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.

Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G.

Cancer Chemother Pharmacol. 2011 Feb;67(2):393-400. doi: 10.1007/s00280-010-1331-z. Epub 2010 May 4.

PMID:
20440618
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, Schiller JH.

Invest New Drugs. 2010 Feb;28(1):91-7. doi: 10.1007/s10637-009-9230-z. Epub 2009 Feb 24.

PMID:
19238328
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.

Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM.

Cancer Chemother Pharmacol. 2009 May;63(6):1147-56. doi: 10.1007/s00280-008-0890-8. Epub 2008 Dec 13.

PMID:
19082825
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.

Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G.

Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.

PMID:
18941749
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk